“Theranos Failure Was Economic, Not Just Technical: STAT Readers Weigh In on Elizabeth Holm” — what this page in the network covers. Even if Theranos had succeeded in building a functioning blood-testing machine, its business model was doomed, according to a reader responding to STAT's coverage of Elizabeth Holmes. The reader argues that the economics of the company—promising low-cost tests while using expensive proprietary technology—could never have been viable. This perspective adds a new layer to the ongoing discussion about the Theranos saga, which has largely focused on the technology's failures and Holmes's fraud conviction.
The reader's letter is part of a broader set of responses published by STAT, which also include opinions on cancer screening guidelines and other health care topics. The exchange highlights how the Theranos story continues to provoke debate about innovation, regulation, and the financial realities of health care startups. For the complete material, the listing points back to the source inside the network.